Radiopharmaceuticals for single-photon emission imaging and for therapy

Federica Orsini, Alice Lorenzoni, Paola Anna Erba, Giuliano Mariani

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

Radiopharmaceuticals contain a radionuclide and an agent to direct the radionuclide to a receptor, antigen, ionic pump, or other site of interest. Some radiopharmaceuticals are simple, such as the ionic form of the radionuclide, while most radiopharmaceuticals have a complex chemical structure where the radionuclide provides a signal, indicating the site of localization of the carrier molecule. Common single-photon radiopharmaceuticals used for oncological diagnosis include the “so-called” technetiated radoipharmaceuticals such as99mTc-bisphosphonates (that accumulate at sites of bone mineral rearrangement),99mTc-Labeled colloids (that are used for lymphoscintigraphy and for imaging of the liver and spleen),99mTc-Hexakis-methoxyisobutyl-isonitrile and99mTc-tetrofosmin (initially employed for myocardial perfusion imaging, then validatyed also for localization of parathyroid adenomas and for identi fi cation of other malignant tumors). The most commonly used radiopharmaceuticals labelled with radioiodine (123I or131I) include Iodide itself (for localization of thyroid tissue) the (underline – db) and the catecholamine analog Metaiodobenzylguanidine (MIBG, for localizing pheochromocytoma and neuroblastoma).201Tl Ionic thallium can be used for tumor perfusion imaging, while111In-Pentetreotide detects overexpression of somatostatin receptors, especially in neuroendocrine tumors and in lesions arising from the neural crest, such as carcinoid, paragangliomas, and medullary thyroid carcinomas.111In-Capromab Pendetide is a murine monoclonal antibody which recognizes a transmembrane glycoprotein expressed by poorly differentiated and metastatic prostate adenocarcinomas.67Ga-Citrate receptors are overexpressed on membranes of both tumor and in fl amatory cells. Common radionuclides used for radiometabolic therapy include131I,153Sm,89Sr,90Y and177Lu. Therapeutic radiopharmaceuticals are employed for therapy of differentiated follicular thyroid carcinomas, for therapy of pheochromocytoma/paraganglioma/neuroblastomas, for bone pain palliation, for radioimmunotherapy of lymphomas, for peptide radioreceptor therapy of neuroendocrine tumors, and for intra-arterial radioembolization of hypervascularized tumors of the liver. Experimental radionuclides for therapy include89Zr and for radioimmunotherapy and peptide radioreceptor therapy as well as alpha emitters, such as223Ra,211At,212Bi,213Bi, and225Ac for treating intractable bone pain as well as for radioimmunotherapy.

Original languageEnglish
Title of host publicationNuclear Oncology: Pathophysiology and Clinical Applications
PublisherSpringer New York
Pages21-34
Number of pages14
ISBN (Print)9780387488943, 9780387488936
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Radiopharmaceuticals
Photons
Radioisotopes
Radioimmunotherapy
Paraganglioma
Neuroendocrine Tumors
Pheochromocytoma
Neuroblastoma
Bone and Bones
Neoplasms
Thyroid Gland
Therapeutics
Follicular Adenocarcinoma
3-Iodobenzylguanidine
Lymphoscintigraphy
Intractable Pain
Somatostatin Receptors
Parathyroid Neoplasms
Peptides
Investigational Therapies

Keywords

  • Nuclear oncology
  • Radioimmune therapy
  • Radioisotopes
  • Radionuclide
  • Radiopharmaceutical
  • Single-photon emission imaging

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Orsini, F., Lorenzoni, A., Erba, P. A., & Mariani, G. (2013). Radiopharmaceuticals for single-photon emission imaging and for therapy. In Nuclear Oncology: Pathophysiology and Clinical Applications (pp. 21-34). Springer New York. https://doi.org/10.1007/978-0-387-48894-3_2

Radiopharmaceuticals for single-photon emission imaging and for therapy. / Orsini, Federica; Lorenzoni, Alice; Erba, Paola Anna; Mariani, Giuliano.

Nuclear Oncology: Pathophysiology and Clinical Applications. Springer New York, 2013. p. 21-34.

Research output: Chapter in Book/Report/Conference proceedingChapter

Orsini, F, Lorenzoni, A, Erba, PA & Mariani, G 2013, Radiopharmaceuticals for single-photon emission imaging and for therapy. in Nuclear Oncology: Pathophysiology and Clinical Applications. Springer New York, pp. 21-34. https://doi.org/10.1007/978-0-387-48894-3_2
Orsini F, Lorenzoni A, Erba PA, Mariani G. Radiopharmaceuticals for single-photon emission imaging and for therapy. In Nuclear Oncology: Pathophysiology and Clinical Applications. Springer New York. 2013. p. 21-34 https://doi.org/10.1007/978-0-387-48894-3_2
Orsini, Federica ; Lorenzoni, Alice ; Erba, Paola Anna ; Mariani, Giuliano. / Radiopharmaceuticals for single-photon emission imaging and for therapy. Nuclear Oncology: Pathophysiology and Clinical Applications. Springer New York, 2013. pp. 21-34
@inbook{99afd68bd51b48dbb3d3a5d509797cc5,
title = "Radiopharmaceuticals for single-photon emission imaging and for therapy",
abstract = "Radiopharmaceuticals contain a radionuclide and an agent to direct the radionuclide to a receptor, antigen, ionic pump, or other site of interest. Some radiopharmaceuticals are simple, such as the ionic form of the radionuclide, while most radiopharmaceuticals have a complex chemical structure where the radionuclide provides a signal, indicating the site of localization of the carrier molecule. Common single-photon radiopharmaceuticals used for oncological diagnosis include the “so-called” technetiated radoipharmaceuticals such as99mTc-bisphosphonates (that accumulate at sites of bone mineral rearrangement),99mTc-Labeled colloids (that are used for lymphoscintigraphy and for imaging of the liver and spleen),99mTc-Hexakis-methoxyisobutyl-isonitrile and99mTc-tetrofosmin (initially employed for myocardial perfusion imaging, then validatyed also for localization of parathyroid adenomas and for identi fi cation of other malignant tumors). The most commonly used radiopharmaceuticals labelled with radioiodine (123I or131I) include Iodide itself (for localization of thyroid tissue) the (underline – db) and the catecholamine analog Metaiodobenzylguanidine (MIBG, for localizing pheochromocytoma and neuroblastoma).201Tl Ionic thallium can be used for tumor perfusion imaging, while111In-Pentetreotide detects overexpression of somatostatin receptors, especially in neuroendocrine tumors and in lesions arising from the neural crest, such as carcinoid, paragangliomas, and medullary thyroid carcinomas.111In-Capromab Pendetide is a murine monoclonal antibody which recognizes a transmembrane glycoprotein expressed by poorly differentiated and metastatic prostate adenocarcinomas.67Ga-Citrate receptors are overexpressed on membranes of both tumor and in fl amatory cells. Common radionuclides used for radiometabolic therapy include131I,153Sm,89Sr,90Y and177Lu. Therapeutic radiopharmaceuticals are employed for therapy of differentiated follicular thyroid carcinomas, for therapy of pheochromocytoma/paraganglioma/neuroblastomas, for bone pain palliation, for radioimmunotherapy of lymphomas, for peptide radioreceptor therapy of neuroendocrine tumors, and for intra-arterial radioembolization of hypervascularized tumors of the liver. Experimental radionuclides for therapy include89Zr and for radioimmunotherapy and peptide radioreceptor therapy as well as alpha emitters, such as223Ra,211At,212Bi,213Bi, and225Ac for treating intractable bone pain as well as for radioimmunotherapy.",
keywords = "Nuclear oncology, Radioimmune therapy, Radioisotopes, Radionuclide, Radiopharmaceutical, Single-photon emission imaging",
author = "Federica Orsini and Alice Lorenzoni and Erba, {Paola Anna} and Giuliano Mariani",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-0-387-48894-3_2",
language = "English",
isbn = "9780387488943",
pages = "21--34",
booktitle = "Nuclear Oncology: Pathophysiology and Clinical Applications",
publisher = "Springer New York",

}

TY - CHAP

T1 - Radiopharmaceuticals for single-photon emission imaging and for therapy

AU - Orsini, Federica

AU - Lorenzoni, Alice

AU - Erba, Paola Anna

AU - Mariani, Giuliano

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Radiopharmaceuticals contain a radionuclide and an agent to direct the radionuclide to a receptor, antigen, ionic pump, or other site of interest. Some radiopharmaceuticals are simple, such as the ionic form of the radionuclide, while most radiopharmaceuticals have a complex chemical structure where the radionuclide provides a signal, indicating the site of localization of the carrier molecule. Common single-photon radiopharmaceuticals used for oncological diagnosis include the “so-called” technetiated radoipharmaceuticals such as99mTc-bisphosphonates (that accumulate at sites of bone mineral rearrangement),99mTc-Labeled colloids (that are used for lymphoscintigraphy and for imaging of the liver and spleen),99mTc-Hexakis-methoxyisobutyl-isonitrile and99mTc-tetrofosmin (initially employed for myocardial perfusion imaging, then validatyed also for localization of parathyroid adenomas and for identi fi cation of other malignant tumors). The most commonly used radiopharmaceuticals labelled with radioiodine (123I or131I) include Iodide itself (for localization of thyroid tissue) the (underline – db) and the catecholamine analog Metaiodobenzylguanidine (MIBG, for localizing pheochromocytoma and neuroblastoma).201Tl Ionic thallium can be used for tumor perfusion imaging, while111In-Pentetreotide detects overexpression of somatostatin receptors, especially in neuroendocrine tumors and in lesions arising from the neural crest, such as carcinoid, paragangliomas, and medullary thyroid carcinomas.111In-Capromab Pendetide is a murine monoclonal antibody which recognizes a transmembrane glycoprotein expressed by poorly differentiated and metastatic prostate adenocarcinomas.67Ga-Citrate receptors are overexpressed on membranes of both tumor and in fl amatory cells. Common radionuclides used for radiometabolic therapy include131I,153Sm,89Sr,90Y and177Lu. Therapeutic radiopharmaceuticals are employed for therapy of differentiated follicular thyroid carcinomas, for therapy of pheochromocytoma/paraganglioma/neuroblastomas, for bone pain palliation, for radioimmunotherapy of lymphomas, for peptide radioreceptor therapy of neuroendocrine tumors, and for intra-arterial radioembolization of hypervascularized tumors of the liver. Experimental radionuclides for therapy include89Zr and for radioimmunotherapy and peptide radioreceptor therapy as well as alpha emitters, such as223Ra,211At,212Bi,213Bi, and225Ac for treating intractable bone pain as well as for radioimmunotherapy.

AB - Radiopharmaceuticals contain a radionuclide and an agent to direct the radionuclide to a receptor, antigen, ionic pump, or other site of interest. Some radiopharmaceuticals are simple, such as the ionic form of the radionuclide, while most radiopharmaceuticals have a complex chemical structure where the radionuclide provides a signal, indicating the site of localization of the carrier molecule. Common single-photon radiopharmaceuticals used for oncological diagnosis include the “so-called” technetiated radoipharmaceuticals such as99mTc-bisphosphonates (that accumulate at sites of bone mineral rearrangement),99mTc-Labeled colloids (that are used for lymphoscintigraphy and for imaging of the liver and spleen),99mTc-Hexakis-methoxyisobutyl-isonitrile and99mTc-tetrofosmin (initially employed for myocardial perfusion imaging, then validatyed also for localization of parathyroid adenomas and for identi fi cation of other malignant tumors). The most commonly used radiopharmaceuticals labelled with radioiodine (123I or131I) include Iodide itself (for localization of thyroid tissue) the (underline – db) and the catecholamine analog Metaiodobenzylguanidine (MIBG, for localizing pheochromocytoma and neuroblastoma).201Tl Ionic thallium can be used for tumor perfusion imaging, while111In-Pentetreotide detects overexpression of somatostatin receptors, especially in neuroendocrine tumors and in lesions arising from the neural crest, such as carcinoid, paragangliomas, and medullary thyroid carcinomas.111In-Capromab Pendetide is a murine monoclonal antibody which recognizes a transmembrane glycoprotein expressed by poorly differentiated and metastatic prostate adenocarcinomas.67Ga-Citrate receptors are overexpressed on membranes of both tumor and in fl amatory cells. Common radionuclides used for radiometabolic therapy include131I,153Sm,89Sr,90Y and177Lu. Therapeutic radiopharmaceuticals are employed for therapy of differentiated follicular thyroid carcinomas, for therapy of pheochromocytoma/paraganglioma/neuroblastomas, for bone pain palliation, for radioimmunotherapy of lymphomas, for peptide radioreceptor therapy of neuroendocrine tumors, and for intra-arterial radioembolization of hypervascularized tumors of the liver. Experimental radionuclides for therapy include89Zr and for radioimmunotherapy and peptide radioreceptor therapy as well as alpha emitters, such as223Ra,211At,212Bi,213Bi, and225Ac for treating intractable bone pain as well as for radioimmunotherapy.

KW - Nuclear oncology

KW - Radioimmune therapy

KW - Radioisotopes

KW - Radionuclide

KW - Radiopharmaceutical

KW - Single-photon emission imaging

UR - http://www.scopus.com/inward/record.url?scp=84913528951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913528951&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-48894-3_2

DO - 10.1007/978-0-387-48894-3_2

M3 - Chapter

SN - 9780387488943

SN - 9780387488936

SP - 21

EP - 34

BT - Nuclear Oncology: Pathophysiology and Clinical Applications

PB - Springer New York

ER -